



## **Disclaimer**



These materials have been prepared by URENCO Limited ("URENCO"). Any person or entity considering making any investment based upon information contained in these materials should ensure that they are properly, independently and professionally advised. These materials were designed for use by specific persons familiar with the business and affairs of URENCO and its subsidiaries and should be considered only in connection with other information, oral or written, provided by URENCO (or any subsidiary) herewith. These materials are not intended to provide the sole basis for evaluating, and should not be considered as a recommendation with respect to, any transaction or other matter.

The information in these materials, which does not purport to be comprehensive, has been provided by URENCO and has not been independently verified. While this information has been prepared in good faith, no representation or warranty, express or implied, is or will be made and no responsibility or liability is or will be accepted by URENCO or any of the URENCO's subsidiaries or by any of their respective officers, employees or agents in relation to the accuracy or completeness of these materials or any other written or oral information made available to any interested party or its advisers and any such liability is expressly disclaimed.

Certain statements contained in these materials, including any descriptions or statements regarding the possible future results of operations, any statement preceded by, followed by or which includes the words "believes", "expects", "intends", "will", "may", "anticipates", or similar expressions, and other statements that are not historical facts, are or may constitute "forward looking statements". Because such statements are inherently subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (a) risks and uncertainties relating to the nuclear industry, consumer demand, political and economic conditions and government regulation and (b) such other risks and uncertainties as are detailed herein. All written and oral forward-looking statements attributable to URENCO are expressly qualified in their entirety by the cautionary statements set forth in this paragraph, and accordingly any person or entity reviewing these materials should not rely on such forward-looking statements.

URENCO gives no undertaking to provide recipients of these materials with access to any additional information or to update these materials or any additional information, or to correct any inaccuracies in it which may become apparent.



- URENCO: Markets
- URENCO: Operational Performance
- URENCO: Financial Performance
- URENCO: Outlook


# Our global presence






# The world energy challenge Demand and population growth through 2050






# **SWU** market equilibrium Primary and secondary supply vs. global demand



# Global market share growth








**2012: 31% market share** 

Source: URENCO





- URENCO: Markets
- URENCO: Operational Performance
- URENCO: Financial Performance
- URENCO: Outlook

# Record delivery and strong operational performance in 2012



#### Record delivery driving revenue increase

23% increase in revenue to €1.6bn

#### Successful capacity expansion

- Ongoing investment increased global capacity to 16,900 tSW/a
- On target to achieve 18,000 tSW/a by 2015
- Further capacity build at URENCO's USA facility

#### Strong delivery against order book

- Strong order book at circa €18bn, extending beyond 2025
- Provides clear long-term revenue visibility

### **Market overview**



- US diffusion plant likely to close by end 2013; USEC faces complex funding challenges for the American Centrifuge Project.
- Russia is on track to remove quotas and trade barriers in all markets. Russia continues to modernise and increase centrifuge plant capacity. Russian market still remains closed to URENCO.
- European gas diffusion operations ended in 2012; competitors' centrifuge plant operational ramp up continues.
- **China** plans largest nuclear new build programme globally. Focused on significantly developing domestic technology capability, potential to deploy additional foreign technology.
- Laser enrichment Licence to construct and operate commercial plant has been issued. Shareholder decision on when to proceed is pending.

# Committed to being close to our customers







- Long-term investment programme 2013 2015
- Year-end capacity: 16,900 tSW/a, target of 18,000 tSW/a by 2015
- Sales to North American customers at 40% of total SWU deliveries





# Our unique strengths



#### **Customer service**

- We consider integrity and 100% delivery against our commitments as paramount
- We have built a reputation for quality and reliability
- Our priority is to deliver for our customers now and in the future

### Skills

 Our workforce is made up of very talented people who operate with great integrity in a highly-regulated industry

# **Safety**

- We always put safety first: for the protection of our employees, the communities where we operate, the suppliers we work with and the customers we supply
- Our focus is on continuous improvement

# **World-leading technology**

 Our centrifuge technology is the world's preferred uranium enrichment technology and recognised as the most cost effective



- URENCO: Markets
- URENCO: Operational Performance
- URENCO: Financial Performance
- URENCO: Outlook

# Five year financial performance



(€million)

#### Revenue



#### **Net Income**



#### **EBITDA**



#### Capital expenditure



#### Cash generated from operations



# Robust results and outlook



Operating performance

Revenue	€1.6bn
EBITDA	+29%
Net income	+12%

Solid financial structure


Capital Expenditure€628mNet financial debt- €135mContinued strong

No significant debt maturities until 2015

operating cash flows


# Revenue, EBITDA, Net Income 2012 vs 2011





#### Group Revenue 2012 vs 2011

Sales increased with record deliveries in 2012




### Group EBITDA 2012 vs 2011

 Higher operating expenditure due to increased deliveries

# Revenue, EBITDA, Net Income 2012 vs 2011






## **Group Net Income 2012 vs 2011**

- Higher depreciation as more cascades now online
- Joint Venture includes impairment of manufacturing assets

# Strong funding facilities



# Funding Facilities As at 31 December 2012 (€3.1billion)



- Sufficient forward cover from committed funding facilities
- €325m of additional debt raised
- Continuing investor interest in URENCO's corporate credit

#### URENCO continues to have access to:

- Commercial Paper market
- Broad range of long-term funding



- URENCO: Markets
- URENCO: Operational Performance
- URENCO: Financial Performance
- URENCO: Outlook

# **Outlook**



- Focus on continuing to serve our customers and strengthen our position as a market leader in uranium enrichment services
- Strong order book extending beyond 2025
- Flattening of demand
- Further expand capacity at US enrichment facility in line with customer commitments
- Continue to increase efficiencies
- Continuous investment in new Tails Management Facility; operations due to start in 2015